NCT05083481 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05083481
Title	A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Astellas Pharma Global Development, Inc.
Indications	Advanced Solid Tumor lung non-small cell carcinoma colorectal cancer
Therapies	ASP1570 + Pembrolizumab ASP1570 ASP1570 + Trifluridine-tipiracil hydrochloride ASP1570 + Docetaxel ASP1570 + Fluorouracil + Leucovorin + Oxaliplatin ASP1570 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ASP1570 + Fluorouracil + Irinotecan + Leucovorin
Age Groups:	senior \| adult
Covered Countries	USA \| FRA \| ESP

Additional content available in CKB BOOST